Join to view full profile
9200 W Wisconsin AveMilwaukee, WI 53226
Dr. Abedin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sameem Abedin is an oncology specialist based in Milwaukee, WI, with a subspecialty in hematologic oncology. He completed his fellowship in hematology and medical oncology at McGaw Medical Center of Northwestern University and has served as an Associate Professor at Froedtert and the Medical College of Wisconsin Froedtert Hospital since 2017. His professional experience includes expertise in hematologic oncology, bone marrow transplantation, and leukemia. Dr. Abedin has contributed to several publications focusing on acute myeloid leukemia and graft-versus-host disease, and is actively involved in clinical trials exploring treatments for these conditions.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2014 - 2017
UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2009
Certifications & Licensure
WI State Medical License 2017 - 2027
IL State Medical License 2014 - 2017
MI State Medical License 2012 - 2016
PA State Medical License 2009 - 2012
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies Start of enrollment: 2017 Mar 20
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2018 Feb 02
- NLA101 in Adults Receiving High Dose Chemotherapy for AML Start of enrollment: 2018 Jan 24
Publications & Presentations
PubMed
- Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.Guru Subramanian Guru Murthy, Bijal Shah, Talha Badar, Jessica Leonard, Adam DuVall
Leukemia. 2026-09-14 - Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.Zachariah DeFilipp, Amin Alousi, John E Levine, Shernan G Holtan, Sameem Abedin
Transplantation and Cellular Therapy. 2026-09-01 - 1 citationsVenetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.Jacqueline S Garcia, Pinkal Desai, Joshua F Zeidner, Ofir Wolach, Thomas W LeBlanc
Leukemia & Lymphoma. 2026-07-29
Abstracts/Posters
- A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...Sameem Abedin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)Sameem Abedin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Actinium Pharmaceuticals Announces Publication of Actimab-a + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal LeukemiaMarch 17th, 2025- Actimab-a Trial Shows Promise for High-Risk AML PatientsMarch 17th, 2025
- Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-a CLAG-M Combination Trial Oral Presentation at ASHDecember 12th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: